A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

H. Tatum, P. J. Thuluvath, E. Lawitz, C. Martorell, M. Demicco, S. Cohen, V. Rustgi, N. Ravendhran, R. Ghalib, J. Hanson, J. Zamparo, J. Zhao, E. Cooney, M. Treitel, E. Hughes

Research output: Contribution to journal › Article › peer-review